Ardill J E S, Erikkson B
Regional Regulatory Peptide Laboratory, Royal Hospitals Trust and Queen's University Belfast, Mulhouse Building, Belfast BT12 6BJ, UK.
Endocr Relat Cancer. 2003 Dec;10(4):459-62. doi: 10.1677/erc.0.0100459.
The measurement of general and specific biochemical markers in patients with neuroendocrine tumours assists with diagnosis and gives an indication of the effectiveness of treatment and they may be used as prognostic indicators. There is much agreement that chromogranin A is the most universally helpful marker; it is found to be elevated in the circulation of about 90% of patients with metastatic neuroendocrine tumours and there are several excellent commercially available kits which give reliable estimations. Specific markers are useful for diagnosis also, and are helpful indicators of the effectiveness of treatment, particularly where tumour bulk may not change as much as tumour activity. Sporadic pancreatic neuroendocrine tumours may secrete more than one peptide and this indicates a worsening prognosis. Because of the wide variation in the progression of neuroendocrine tumours, a prognostic indicator gives a significant advantage to the clinician in order to facilitate optimum treatment at the optimum stage of disease. Both chromogranin A and neurokinin A have been used as powerful prognostic indicators for midgut carcinoid tumours.
对神经内分泌肿瘤患者的一般和特定生化标志物进行检测有助于诊断，并能提示治疗效果，还可作为预后指标。人们普遍认为嗜铬粒蛋白A是最具普遍帮助的标志物；在约90%的转移性神经内分泌肿瘤患者的循环系统中发现其水平升高，并且有几种优秀的商用试剂盒可提供可靠的检测结果。特定标志物对诊断也很有用，并且是治疗效果的有用指标，特别是在肿瘤体积变化可能不如肿瘤活性变化大的情况下。散发性胰腺神经内分泌肿瘤可能分泌不止一种肽，这表明预后较差。由于神经内分泌肿瘤进展差异很大，预后指标能为临床医生带来显著优势，以便在疾病的最佳阶段促进最佳治疗。嗜铬粒蛋白A和神经激肽A都已被用作中肠类癌肿瘤的有力预后指标。
